Apalutamide
- Generic Name
- Apalutamide
- Brand Names
- Erleada
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15F4N5O2S
- CAS Number
- 956104-40-8
- Unique Ingredient Identifier
- 4T36H88UA7
- Background
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...
- Indication
Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- Androgen Deprivation Therapy
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 333
- Registration Number
- NCT05884398
- Locations
- 🇺🇸
Urology Centers Of Alabama, Homewood, Alabama, United States
🇺🇸Arizona Urology Specialists, Tucson, Arizona, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 26
- Registration Number
- NCT05751941
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05740488
- Locations
- 🇨🇳
zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 47
- Registration Number
- NCT05717582
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Pudong Hospital, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center Xuhui Hospital, Shanghai, Shanghai, China
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Edwin Posadas, MD
- Target Recruit Count
- 100
- Registration Number
- NCT05534646
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Huntsman Cancer Institute and Hospital, Salt Lake City, Utah, United States
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT05521698
- Locations
- 🇺🇸
University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
🇺🇸University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT05422911
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, New York, United States
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2022-08-16
- Target Recruit Count
- 900
- Registration Number
- NCT05406999
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.